Core Viewpoint - Jincheng Pharmaceutical (300233) announced the approval of a supplemental application for injectable Cefuroxime Sodium by the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Approval - The approved drug, injectable Cefuroxime Sodium, is primarily used for treating infections caused by bacteria sensitive to Cefuroxime, including respiratory and ENT infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, and bone and joint infections [1]

人民财讯1月21日电，毅昌科技（002420）1月21日发布业绩预告，预计2025年归母净利1.5亿元—2.25亿 元，同比增长58%—138%。报告期内，公司通过摆脱单一传统业务结构，向高附加值、高成长性的汽 车与新能源行业加速布局，实现业务升级。基于公司的发展战略和规划，进一步优化公司的资源配置， 子公司江苏毅昌科技有限公司、江苏设计谷科技有限公司转让其持有的土地及相关项目资产，资产处置 收益约1.4亿元计入非经常性损益。 ...

人民财讯1月21日电，翱捷科技(688220)1月21日公告，公司预计2025年实现归属于母公司所有者的净利 润为亏损3.99亿元左右，较2024年亏损金额减少2.94亿元左右，报告期内，随着公司产品的不断丰富， 产品覆盖的应用场景进一步拓展，芯片销量较上年同期实现大幅增长，带动整体营业收入实现持续增 长，收入增长幅度为12.73%左右；公司在研发方面继续保持大额投入，预计2025年研发投入13.02亿元 左右，较上年同期增长4.89%左右。 ...

人民财讯1月21日电，广东省人民政府办公厅印发《广东省人工智能赋能交通运输高质量发展若干政策 措施》，其中提到，加强交通运输数据供给。以交通行业数字底座建设为引领，深化数据汇聚，强化数 据治理，提升行业数据质量，扩大优质数据供给。构建交通行业数据资源目录体系，推动公路、铁路、 港航、运输等全要素数据标准化、规范化建设。开展公共数据授权运营试点，探索交通数据要素产品化 开发，加快构建智慧路网、智慧养护、数字港航、智慧出行等应用场景高质量数据集，为人工智能能力 提升和应用场景落地提供关键支撑。 ...

人民财讯1月21日电，企查查APP显示，近日，泊壤(安吉)农业旅游有限公司成立，法定代表人为易萱， 注册资本500万人民币，经营范围含旅游业务、组织文化艺术交流活动、商标代理等，由小红书旗下璞 真乡里(上海)旅游文化有限公司全资持股。 ...

Core Viewpoint - The launch of the world's first "Hepatitis B Cure AI Assistant" by Yidu Technology in collaboration with Chongqing Medical University Second Affiliated Hospital aims to provide a comprehensive closed-loop service for Hepatitis B management, addressing issues such as fragmented information and inefficient clinical research recruitment [1][2]. Group 1: AI Assistant Features - The AI assistant is built on a medical domain-specific large model and offers a one-stop service covering screening, diagnosis, treatment, follow-up, and research [1]. - It operates on a smart management system that integrates clinical pathways and utilizes retrieval-augmented generation (RAG) technology to create a digital support system throughout the disease management process [1][2]. - The assistant acts as a "personal health manager," enabling continuous intelligent services for patients, including follow-ups, personalized education, health consultations, and appointment reminders [1]. Group 2: Clinical Collaboration and Data Integration - The AI assistant enhances clinical collaboration by covering the entire process from high-risk population screening to long-term follow-up and rehabilitation guidance, while also bridging the gap between research and clinical data [2]. - The collaboration between Yidu Technology and Chongqing Medical University has led to the establishment of a high-quality "Hepatitis B Specialty Database," which supports the AI assistant's capabilities [2]. - The assistant's effectiveness has been validated in clinical settings, demonstrating its ability to provide personalized risk assessments and decision support based on complex medical logic [2]. Group 3: Future Developments - The AI assistant is currently undergoing testing on both mobile and computer platforms, with plans for patients to access pre-consultation services and expert recommendations through a user-friendly interface [3]. - Yidu Technology plans to explore innovative services such as specialized large models and digital avatars for doctors, expanding the boundaries of intelligent management in the field of liver disease [3].

近期，深圳市红筹投资有限公司、海南世纪前沿私募基金管理有限公司等私募投资机构接到群众反映， 称有不法分子利用其名义进行荐股、配资、非法投资、诈骗、诱导下载不明软件等违法违规活动。 （文章来源：证券时报网） "人民鉴真"资本市场信息服务平台经与上述机构求证获悉，其机构和所有工作人员从未开展、亦从未授 权任何第三方机构或个人开展任何荐股或操作指导等业务；请广大投资者务必提高警惕，切勿轻信此类 非法宣传，切勿下载任何非正常渠道提供的投资交易软件，以免遭受损失。 ...

近期，深圳市红筹投资有限公司、海南世纪前沿私募基金管理有限公司等私募投资机构接到群众反映， 称有不法分子利用其名义进行荐股、配资、非法投资、诈骗、诱导下载不明软件等违法违规活动。 "人民鉴真"资本市场信息服务平台经与上述机构求证获悉，其机构和所有工作人员从未开展、亦从未授 权任何第三方机构或个人开展任何荐股或操作指导等业务；请广大投资者务必提高警惕，切勿轻信此类 非法宣传，切勿下载任何非正常渠道提供的投资交易软件，以免遭受损失。 ...

Core Viewpoint - Roman Co., Ltd. (605289) expects to achieve a net profit attributable to shareholders of 50 million to 60 million yuan for the fiscal year 2025, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The company anticipates a significant increase in net profit compared to the previous year, indicating a successful recovery from losses [1] - The projected net profit range of 50 million to 60 million yuan reflects a positive outlook for the company's financial health [1] Group 2: Business Development - During the reporting period, the company completed the acquisition of control over Shanghai Wutongshu High-tech Co., Ltd., which has been incorporated into the consolidated financial statements [1] - The orderly delivery of new business project orders has contributed to a steady increase in production capacity utilization [1] - The gradual release of scale effects has effectively driven significant growth in the company's operating performance during this period [1]

人民财讯1月21日电，企查查APP显示，近日，财达国民康恒(雄安)科创股权投资基金合伙企业(有限合 伙)成立，出资额5105.45万元，经营范围包含：创业投资(限投资未上市企业)；以私募基金从事股权投 资、投资管理、资产管理等活动；以自有资金从事投资活动。企查查股权穿透显示，该合伙企业由国民 信托有限公司、财达资本管理有限公司共同持股。 ...